Impact Biomedical Inc. IBO
Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026
Impact Biomedical Inc. (IBO) is a healthcare company listed in the US with a market value of about $44M. In the twelve months to September 30, 2026 it had revenue of $38000 and net income of $2M, a net margin of 4247.4%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).
Key numbers: a P/E of 0.3, a 5-year average ROIC of -54%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Impact Biomedical
Impact Biomedical is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2024. Revenue went from $50000 in 2022 to $32000 in 2025, a decline of about 13.8% a year. It was profitable in 0 of the last 4 years in our data. Its share count fell by 55% over three years (buybacks). It spends 1062% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $38000 | $32000 | — | — | $50000 |
| Net income | $2M | -$12M | -$25M | -$4M | -$7M |
| Free cash flow | — | — | — | -$3M | -$3M |
| EPS (diluted) | $17.47 | $-0.38 | $-2.30 | $-0.07 | $-0.10 |
| Net margin | 4247.4% | -36993.8% | — | — | -14510.0% |
| ROIC | — | -27.9% | -172.9% | -8.5% | -7.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Impact Biomedical’s P/E ratio?
About 0.3, based on the last twelve months of diluted earnings per share.
Is Impact Biomedical stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Impact Biomedical pay a dividend?
Not currently.
Is Impact Biomedical a good stock to buy?
We do not give buy or sell advice. Impact Biomedical scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.